{"id":3469,"date":"2025-03-06T19:39:40","date_gmt":"2025-03-06T19:39:40","guid":{"rendered":"http:\/\/blog.valuengine.com\/?p=3469"},"modified":"2025-03-06T19:39:40","modified_gmt":"2025-03-06T19:39:40","slug":"health-care-sector-trying-to-bounce-back","status":"publish","type":"post","link":"http:\/\/blog.valuengine.com\/index.php\/health-care-sector-trying-to-bounce-back\/","title":{"rendered":"Health Care Sector Trying to Bounce Back"},"content":{"rendered":"<p><span style=\"font-weight: 400;\">I will often feature stocks rated buy or strong buy in highly rated sectors.\u00a0 This one is a departure.\u00a0 The healthcare sector is most commonly represented by the Select Sector SPDR Healthcare ETF, <\/span><b>XLV. <\/b><span style=\"font-weight: 400;\">It faced a challenging year in 2024, underperforming the S&amp;P 500 Index by a staggering 22.4%. This massive performance shortfall resulted in $7.4 billion in outflows from <\/span><b>XLV<\/b><span style=\"font-weight: 400;\">, marking the largest outflows among the 11 Select Sector SPDR ETFs sectors by a wide margin. But this poor performance has changed over the past two months with the Medical oriented ETFs substantially outperforming the S&amp;P 500 year to date.<\/span><\/p>\n<h5 style=\"text-align: center;\"><b>All 5,200+ stocks US and Canadian stocks, 16 sector groups, 200+ industries, and 700+\u00a0 ETFs have been updated: Two-week free trial:<\/b><a href=\"https:\/\/ww2.valuengine.com\/products-and-pricing\/\"><b> www.ValuEngine.com<\/b><\/a><b>\u00a0\u00a0<\/b><\/h5>\n<p><span style=\"font-weight: 400;\">The significant underperformance of the Healthcare Select Sector Index over the longer time frame can be attributed to numerous factors. The sector grappled with regulatory uncertainties, escalating operational costs, and shifting market sentiments. Despite a substantial increase in total US healthcare spending, which more than tripled from $1.4 trillion in 2000 to $4.9 trillion in 2023, the sector struggled to maintain investor confidence.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The healthcare sector&#8217;s weight within the S&amp;P 500 is approaching a 25-year low. This decline in weight indicates a reduced influence on the sector and contribution to the overall market performance. The juxtaposition of increasing healthcare expenses and declining market performance presents a paradox that warrants a deeper examination.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Several factors contributed to the significant outflows from Healthcare sector ETFs in 2024:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Regulatory Uncertainties: The sector faced ongoing uncertainties regarding healthcare policies and regulations, which created an unpredictable environment for investors.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Rising Operational Costs: Healthcare companies experienced escalating costs related to research and development, compliance, and labor, affecting their profitability and attractiveness to investors.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Market Sentiments: Shifting market sentiments and diminished investor confidence in the sector&#8217;s future prospects\u00a0<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">In addition to <\/span><b>XLV<\/b><span style=\"font-weight: 400;\">, the next two largest healthcare ETFs in terms of Assets Under Management (AUM) are:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Vanguard Healthcare ETF (<\/span><b>VHT<\/b><span style=\"font-weight: 400;\">): This ETF offers exposure to a broad range of healthcare-related stocks, including pharmaceuticals, biotechnology, medical devices, and healthcare providers.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">iShares U.S. Healthcare ETF (<\/span><b>IYH<\/b><span style=\"font-weight: 400;\">): This ETF seeks to track the investment results of an index composed of U.S. equities in the healthcare sector.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">The broad healthcare industry contains an important high-growth-potential but high-risk subsector: biotech stocks. The biotech subsector represents a dynamic and rapidly evolving segment of the healthcare industry. This subsector is characterized by significant research and development activities, leading to groundbreaking innovations in medical treatments, diagnostics, and technologies. However, the biotech subsector is also associated with unique risks and opportunities that investors and stakeholders must navigate.<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">The risk associated with individual biotech stock investments are why many investors seek exposure to the biotech subsector through exchange-traded funds (ETFs). These can provide a diversified and relatively low-risk option.\u00a0 The three largest biotech ETFs by AUM are the iShares Nasdaq Biotechnology ETF (<\/span><b>IBB<\/b><span style=\"font-weight: 400;\">), SPDR S&amp;P Biotech ETF (<\/span><b>XBI<\/b><span style=\"font-weight: 400;\">) and the First Trust NYSE Arca Biotechnology Index Fund (<\/span><b>FBT<\/b><span style=\"font-weight: 400;\">).\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Comparing recent price performance compared with ETFs representing other S&amp;P 500 Sectors reveals that the Healthcare Select Sector SPDR Fund (<\/span><b>XLV<\/b><span style=\"font-weight: 400;\">) has shown mixed performance relative to its peers. While sectors like Technology (<\/span><b>XLK<\/b><span style=\"font-weight: 400;\">) and Consumer Discretionary (<\/span><b>XLY<\/b><span style=\"font-weight: 400;\">) have experienced robust gains driven by strong earnings growth and consumer spending, XLV has faced headwinds due to regulatory concerns and cost pressures.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The Energy Select Sector SPDR Fund (<\/span><b>XLE<\/b><span style=\"font-weight: 400;\">), on the other hand, benefited from rising oil prices and geopolitical tensions, resulting in significant outperformance. Conversely, the Financial Select Sector SPDR Fund (<\/span><b>XLF<\/b><span style=\"font-weight: 400;\">) struggled amid economic uncertainties and interest rate fluctuations, mirroring some of the challenges faced by <\/span><b>XLV<\/b><span style=\"font-weight: 400;\">.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">This chart compares three broad healthcare ETFs and three biotech ETFs. Data is sourced from ETFdb.com, a VettaFI company. The SPDR Portfolio S&amp;P 500 ETF (<\/span><b>SPLG<\/b><span style=\"font-weight: 400;\">) is used instead of <\/span><b>SPY<\/b><span style=\"font-weight: 400;\"> due to its more efficient structure and lower expense ratio (0.02% for <\/span><b>SPLG<\/b><span style=\"font-weight: 400;\"> vs. 0.095% for <\/span><b>SPY<\/b><span style=\"font-weight: 400;\">). Unlike the outdated <\/span><b>SPY<\/b><span style=\"font-weight: 400;\">, <\/span><b>SPLG<\/b><span style=\"font-weight: 400;\"> can lend securities and reinvest dividends, reducing expenses. Alternatively, the S&amp;P 500 ETF that now has the greater amount of ETF assets is the Vanguard S&amp;P 500 ETF, <\/span><b>VOO.\u00a0 <\/b><span style=\"font-weight: 400;\">For most investors, the difference between the 0.03% and 0.02% is immaterial. If you prefer the Vanguard brand, <\/span><b>VOO <\/b><span style=\"font-weight: 400;\">is just as good.\u00a0 However, as a quant, I go for the lowest expense ratio. For these reasons, I prefer using <\/span><b>SPLG<\/b><span style=\"font-weight: 400;\"> for comparative charts like this one in the healthcare industry.<\/span><\/p>\n<h5 style=\"text-align: center;\"><b>Current ValuEngine reports on all covered stocks and ETFS can be viewed<\/b><a href=\"https:\/\/valuengine.com\/dashboard\/report\"><b> HERE<\/b><\/a><\/h5>\n<table>\n<tbody>\n<tr>\n<td><span style=\"font-weight: 400;\">Ticker<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Name<\/span><\/td>\n<td><span style=\"font-weight: 400;\">VE Rating<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Assets ($Bil)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">YTD Price Change<\/span><\/td>\n<td><span style=\"font-weight: 400;\">1 Year Returns<\/span><\/td>\n<td><span style=\"font-weight: 400;\">5 Year Returns<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Expense Ratio\u00a0<\/span><\/td>\n<td><span style=\"font-weight: 400;\"> Annual Dividend Yield %<\/span><\/td>\n<td><span style=\"font-weight: 400;\"># of Holdings<\/span><\/td>\n<\/tr>\n<tr>\n<td><b>XLV<\/b><\/td>\n<td><span style=\"font-weight: 400;\">Healthcare Select Sector SPDR Fund<\/span><\/td>\n<td><b>1<\/b><\/td>\n<td><span style=\"font-weight: 400;\">$38.4\u00a0<\/span><\/td>\n<td><span style=\"font-weight: 400;\">6.44%<\/span><\/td>\n<td><span style=\"font-weight: 400;\">1.08%<\/span><\/td>\n<td><b>8.93%<\/b><\/td>\n<td><b>0.09%<\/b><\/td>\n<td><span style=\"font-weight: 400;\">1.6%<\/span><\/td>\n<td><span style=\"font-weight: 400;\">124<\/span><\/td>\n<\/tr>\n<tr>\n<td><b>VHT<\/b><\/td>\n<td><span style=\"font-weight: 400;\">Vanguard Healthcare ETF<\/span><\/td>\n<td><span style=\"font-weight: 400;\">1<\/span><\/td>\n<td><span style=\"font-weight: 400;\">$17.0\u00a0<\/span><\/td>\n<td><span style=\"font-weight: 400;\">5.95%<\/span><\/td>\n<td><span style=\"font-weight: 400;\">1.31%<\/span><\/td>\n<td><span style=\"font-weight: 400;\">8.00%<\/span><\/td>\n<td><b>0.09%<\/b><\/td>\n<td><span style=\"font-weight: 400;\">1.4%<\/span><\/td>\n<td><b>413<\/b><\/td>\n<\/tr>\n<tr>\n<td><b>IBB<\/b><\/td>\n<td><span style=\"font-weight: 400;\">iShares Biotech ETF<\/span><\/td>\n<td><span style=\"font-weight: 400;\">1<\/span><\/td>\n<td><span style=\"font-weight: 400;\">$6.5\u00a0<\/span><\/td>\n<td><span style=\"font-weight: 400;\">5.07%<\/span><\/td>\n<td><span style=\"font-weight: 400;\">1.55%<\/span><\/td>\n<td><span style=\"font-weight: 400;\">2.68%<\/span><\/td>\n<td><span style=\"font-weight: 400;\">0.45%<\/span><\/td>\n<td><span style=\"font-weight: 400;\">0.3%<\/span><\/td>\n<td><span style=\"font-weight: 400;\">258<\/span><\/td>\n<\/tr>\n<tr>\n<td><b>XBI<\/b><\/td>\n<td><span style=\"font-weight: 400;\">SPDR S&amp;P Biotech ETF<\/span><\/td>\n<td><span style=\"font-weight: 400;\">1<\/span><\/td>\n<td><span style=\"font-weight: 400;\">$6,1\u00a0<\/span><\/td>\n<td><span style=\"font-weight: 400;\">1.82%<\/span><\/td>\n<td><span style=\"font-weight: 400;\">-2.47%<\/span><\/td>\n<td><span style=\"font-weight: 400;\">-1.20%<\/span><\/td>\n<td><span style=\"font-weight: 400;\">0.35%<\/span><\/td>\n<td><span style=\"font-weight: 400;\">0.1%<\/span><\/td>\n<td><span style=\"font-weight: 400;\">280<\/span><\/td>\n<\/tr>\n<tr>\n<td><b>IYH<\/b><\/td>\n<td><span style=\"font-weight: 400;\">iShares U.S. Healthcare ETF<\/span><\/td>\n<td><span style=\"font-weight: 400;\">2<\/span><\/td>\n<td><span style=\"font-weight: 400;\">$3.2<\/span><\/td>\n<td><span style=\"font-weight: 400;\">5.65%<\/span><\/td>\n<td><span style=\"font-weight: 400;\">0.91%<\/span><\/td>\n<td><span style=\"font-weight: 400;\">8.21%<\/span><\/td>\n<td><span style=\"font-weight: 400;\">0.39%<\/span><\/td>\n<td><span style=\"font-weight: 400;\">1.2%<\/span><\/td>\n<td><span style=\"font-weight: 400;\">107<\/span><\/td>\n<\/tr>\n<tr>\n<td><b>FBT<\/b><\/td>\n<td><span style=\"font-weight: 400;\">First Trust NYSE Arca Biotech Index Fund<\/span><\/td>\n<td><b>4<\/b><\/td>\n<td><span style=\"font-weight: 400;\">$1.2\u00a0<\/span><\/td>\n<td><b>7.03%<\/b><\/td>\n<td><b>19.3%<\/b><\/td>\n<td><span style=\"font-weight: 400;\">3.08%<\/span><\/td>\n<td><span style=\"font-weight: 400;\">0.56%<\/span><\/td>\n<td><span style=\"font-weight: 400;\">0.7%<\/span><\/td>\n<td><span style=\"font-weight: 400;\">31<\/span><\/td>\n<\/tr>\n<tr>\n<td><b><i>SPLG<\/i><\/b><\/td>\n<td><i><span style=\"font-weight: 400;\">SPDR Portfolio S&amp;P 500 ETF<\/span><\/i><\/td>\n<td><i><span style=\"font-weight: 400;\">3<\/span><\/i><\/td>\n<td><i><span style=\"font-weight: 400;\">$59.8\u00a0<\/span><\/i><\/td>\n<td><i><span style=\"font-weight: 400;\">-0.8%<\/span><\/i><\/td>\n<td><i><span style=\"font-weight: 400;\">17.4%<\/span><\/i><\/td>\n<td><b><i>14.2%<\/i><\/b><\/td>\n<td><b><i>0.02%<\/i><\/b><\/td>\n<td><i><span style=\"font-weight: 400;\">1.4%<\/span><\/i><\/td>\n<td><i><span style=\"font-weight: 400;\">500<\/span><\/i><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h5 style=\"text-align: center;\"><b>Current ValuEngine reports on all covered stocks and ETFS can be viewed<\/b><a href=\"https:\/\/valuengine.com\/dashboard\/report\"><b> HERE<\/b><\/a><\/h5>\n<p><span style=\"font-weight: 400;\">All six healthcare industry ETFs have underperformed <\/span><b>SPLG<\/b><span style=\"font-weight: 400;\"> over the time periods shown. However, in January and February (&#8220;YTD&#8221; column), all these ETFs significantly outperformed <\/span><b>SPLG<\/b><span style=\"font-weight: 400;\">, which was affected by &#8220;Magnificent Seven&#8221; tech stocks. The First Trust NYSE Arca ETF, an equally weighted ETF with only 30 stocks, outperformed the S&amp;P 500 in the past 12 months, which none of the others did. Over five years, <\/span><b>XLV<\/b><span style=\"font-weight: 400;\">, the most-cited ETF for the sector, had the highest return among the six.\u00a0\u00a0<\/span><\/p>\n<p><b>The question is whether the technical strength shown by the two-month rebound for Healthcare ETFs will continue.<\/b><span style=\"font-weight: 400;\">\u00a0 Fidelity released a recent research report making a bull case for the sector.\u00a0 They refer to it as a very innovative sector with strong long-term drivers of growth.\u00a0 They add that many of the stocks that comprise the sector are currently selling at cheap valuations and multiples relative to the market as a whole.\u00a0 To me, this case is compelling for long term investors.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Unfortunately for the next one-month and twelve month periods, our models don\u2019t agree with this assessment.\u00a0 One of the distinguishing facets of ValuEngine is that we have an approximately equal number of stocks that are rated <\/span><b>1 <\/b><span style=\"font-weight: 400;\">and <\/span><b>2 <\/b><span style=\"font-weight: 400;\">(Strong sell and sell, respectively) as are rated <\/span><b>4 <\/b><span style=\"font-weight: 400;\">and <\/span><b>5 <\/b><span style=\"font-weight: 400;\">(Strong buy and buy respectively).\u00a0 The distribution resembles an elongated bell curve with the majority of stocks being rated <\/span><b>3<\/b><span style=\"font-weight: 400;\">, about 30% rated either <\/span><b>2<\/b><span style=\"font-weight: 400;\"> or<\/span><b> 4,<\/b><span style=\"font-weight: 400;\"> and roughly 10% rated either <\/span><b>1 <\/b><span style=\"font-weight: 400;\">or <\/span><b>5.<\/b><span style=\"font-weight: 400;\"> This gives us the ability to feature a sector that has absorbed a three-year decline while the market has been rising.\u00a0\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The consensus of analysts\u2019 four-quarter earnings estimates do not indicate that an earnings growth spurt will happen during that period.\u00a0 Consequently, the ValuEngine forecast ratings for these ETFs and the sector are mostly very poor.\u00a0 Four of the six ETFs in this analysis get our Strong Sell rating of <\/span><b>1.\u00a0 IYH, <\/b><span style=\"font-weight: 400;\">the iShares Healthcare ETF is slightly better in projected relative price change with a Sell rating of <\/span><b>2.\u00a0 <\/b><span style=\"font-weight: 400;\">The one ray of hope is the equally weighted First Trust NYSE Arca Biotechnology Fund with a Buy rating of <\/span><b>4<\/b><span style=\"font-weight: 400;\">.\u00a0\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The ValuEngine Sector Report rates Healthcare (defined as \u201cMedical\u201d in the report) 12<\/span><span style=\"font-weight: 400;\">th<\/span><span style=\"font-weight: 400;\"> among our 15 sectors for relative year-ahead projected performance.\u00a0 However, two large cap US healthcare stocks receive a <\/span><b>5 <\/b><span style=\"font-weight: 400;\">(Strong Buy) rating. The two stocks are Intuitive Surgical (<\/span><b>ISRG<\/b><span style=\"font-weight: 400;\">) and Bristol Myers (<\/span><b>BMY).\u00a0\u00a0<\/b><\/p>\n<h5 style=\"text-align: center;\"><b>Current ValuEngine reports on all covered stocks and ETFS can be viewed<\/b><a href=\"https:\/\/valuengine.com\/dashboard\/report\"><b> HERE<\/b><\/a><\/h5>\n<p><strong>Intuitive Surgical<\/strong><span style=\"font-weight: 400;\"> develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables surgical procedures using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic endoluminal procedures enabling minimally invasive biopsies in the lung. It also provides a suite of\u00a0related products and services. <\/span><b>IRSG <\/b><span style=\"font-weight: 400;\">was incorporated in Sunnyvale CA in 1995. On Feb. 28, <\/span><b>IRSG <\/b><span style=\"font-weight: 400;\">was selling at $573.15.\u00a0 This set its P\/E multiple at an extremely pricey 89.9. Its advanced methods have caused it to trade like a cutting edge tech company rather than a healthcare company.\u00a0\u00a0<\/span><\/p>\n<p><strong>Bristol Myers <\/strong><span style=\"font-weight: 400;\">discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company&#8217;s products include Eliquis for reduction in risk of stroke\/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT\/PE; Opdivo for various anti-cancer indications; Pomalyst\/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel to treat patients with Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of relapsed\/refractory multiple myeloma; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Reblozyl to treat anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis The company was founded in Princeton, NJ in 1889. Its P\/E ratio is undefined due to a trailing 12-month earnings number of -$4.41, which reflects its previous troubles.\u00a0 Removing extraordinary items that dragged the stock down, VE has its P\/E ratio at 19.8.\u00a0 However, its dividend yield of 4.2% pegs it as a value stock.\u00a0 Analysts\u2019 predictions of a jump in the 12-month ahead earnings projections help<\/span><b> BMY<\/b><span style=\"font-weight: 400;\"> earn our highest ranking.\u00a0\u00a0<\/span><\/p>\n<h5 style=\"text-align: center;\"><b>Financial Advisory Services based on ValuEngine research available:\u00a0 <\/b><a href=\"http:\/\/www.valuenginecapital.com\/\"><b>www.ValuEngineCapital.com<\/b><\/a><\/h5>\n<p><span style=\"font-weight: 400;\">My conclusion is that while a bullish case can be made for the Healthcare (or Medical) sector as a whole, I urge caution as our model\u2019s ratings of the ETFs representing the the sector as a whole indicate that investing in an eventual recovery for the sector may be a bit premature.\u00a0 However, there are a number of well-followed stocks to research and consider for investing including Intuitive Surgical and Bristol Myers.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">________________________________________________________________<\/span><\/p>\n<h5><b>By Herbert Blank<\/b><\/h5>\n<h5><b>Senior Quantitative Analyst, ValuEngine Inc<\/b><\/h5>\n<h5><a href=\"http:\/\/www.valuengine.com\/\"><b>www.ValuEngine.com<\/b><\/a><\/h5>\n<h5><b>support@ValuEngine.com<\/b><\/h5>\n<h5><b>All of the over 4,200 stocks, 16 sector groups, over 250 industries, and 600 ETFs have been updated on<\/b><a href=\"http:\/\/www.valuengine.com\/\"><b> www.ValuEngine.com<\/b><\/a><\/h5>\n<h5><b>Financial Advisory Services based on ValuEngine research available through<\/b><a href=\"http:\/\/www.valuenginecapital.com\/\"><b> ValuEngine Capital Management, LLC<\/b><\/a><\/h5>\n<h5><b>Free Two-Week Trial to all 5,000 plus equities covered by ValuEngine<\/b><a href=\"https:\/\/ww2.valuengine.com\/products-and-pricing\/\"><b> HERE<\/b><\/a><\/h5>\n<p><b>Subscribers log in <\/b><a href=\"https:\/\/valuengine.com\/dashboard\/login\"><b>HERE<\/b><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>I will often feature stocks rated buy or strong buy in highly rated sectors.\u00a0 This one is a departure.\u00a0 The healthcare sector is most commonly represented by the Select Sector SPDR Healthcare ETF, XLV. It faced a challenging year in 2024, underperforming the S&amp;P 500 Index by a staggering 22.4%. This massive performance shortfall resulted &#8230; <a title=\"Health Care Sector Trying to Bounce Back\" class=\"read-more\" href=\"http:\/\/blog.valuengine.com\/index.php\/health-care-sector-trying-to-bounce-back\/\" aria-label=\"More on Health Care Sector Trying to Bounce Back\">Read more<\/a><\/p>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[130,1,39],"tags":[2566,2569,2567,1760,1761,1719,1806,1753,2571,2572,2573,2574,432,1731,1807,2568,2502,2570,2565,1510,1911,2290,28,1659,63,2410,1808,2276],"_links":{"self":[{"href":"http:\/\/blog.valuengine.com\/index.php\/wp-json\/wp\/v2\/posts\/3469"}],"collection":[{"href":"http:\/\/blog.valuengine.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/blog.valuengine.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/blog.valuengine.com\/index.php\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"http:\/\/blog.valuengine.com\/index.php\/wp-json\/wp\/v2\/comments?post=3469"}],"version-history":[{"count":1,"href":"http:\/\/blog.valuengine.com\/index.php\/wp-json\/wp\/v2\/posts\/3469\/revisions"}],"predecessor-version":[{"id":3470,"href":"http:\/\/blog.valuengine.com\/index.php\/wp-json\/wp\/v2\/posts\/3469\/revisions\/3470"}],"wp:attachment":[{"href":"http:\/\/blog.valuengine.com\/index.php\/wp-json\/wp\/v2\/media?parent=3469"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/blog.valuengine.com\/index.php\/wp-json\/wp\/v2\/categories?post=3469"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/blog.valuengine.com\/index.php\/wp-json\/wp\/v2\/tags?post=3469"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}